Theravance Biopharma completed enrollment in the CYPRESS study for Ampreloxetine, a drug designed to address nOH in MSA.
2 reports, 2 independent
Updated Aug 25
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Theravance Biopharma completed enrollment in the CYPRESS study for Ampreloxetine, a drug designed to address nOH in MSA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Theravance Biopharma (United States)
company in San Francisco, United States
Nothing else this week.
-
MSA
Czech company
Nothing else this week.
Coverage
Newest first; wire copies grouped- PR NewswireTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy Topline resu
- GuruFocus.comTheravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the fu